SCHEMBL578997

SCHEMBL578997

CN1CCC(N(C)C(=O)c2ccc(Nc3ncc(C(F)(F)F)c(Cl)n3)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 4/20 0.51
AURKA O14965 1/20 0.51
EGFR P00533 1/20 0.51
NTRK1 P04629 1/20 0.51
CDK1 P06493 1/20 0.51
IGF1R P08069 1/20 0.51
KIT P10721 1/20 0.51
EPHA1 P21709 1/20 0.51
CDK2 P24941 1/20 0.51
FLT3 P36888 1/20 0.51
BMX P51813 1/20 0.51
CDK6 Q00534 1/20 0.51
PAK1 Q13153 1/20 0.51
ALK Q9UM73 1/20 0.51
JAK2 O60674 11/20 0.49
JAK1 P23458 11/20 0.49
SYK P43405 2/20 0.49
PTK2 Q05397 3/20 0.49
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12438378 0.90 JAK3 (0.52) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL10148425 0.89 JAK3 (0.54) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL10149268 0.87 SYK (0.52) JAK3JAK2JAK1SYKPTK2
SCHEMBL2324528 0.87 JAK2 (0.51) AURKAIGF1RJAK2JAK1SYK
Bicarbonate SCHEMBL579108 0.83 FLT3 (0.64) JAK3AURKAEGFRNTRK1CDK1
Bicarbonate SCHEMBL579262 0.83 KIT (0.64) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL13808086 0.83 FLT3 (0.61) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL579261 0.83 FLT3 (0.61) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL578790 0.82 FLT3 (0.55) JAK3AURKAEGFRNTRK1CDK1
SCHEMBL13808085 0.82 FLT3 (0.55) JAK3AURKAEGFRNTRK1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623887-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-07 US disclosed
US-8623887-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-07 US disclosed
US-8623887-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-07 US disclosed
US-20130281429-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-24 US disclosed
US-20130281429-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-24 US disclosed
US-20130281429-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-24 US disclosed
EP-2027107-B1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-02-15 EP disclosed
US-20110251174-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-13 US disclosed
US-20110251174-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-13 US disclosed
US-20110251174-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-13 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090163467-A1 New compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
CN-101443325-A 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors SANOFI AVENTIS DEUTSCHLAND (DE) 2009-05-27 CN disclosed
CN-101213179-A 2, 4-diamino-pyrimidines as Aurora inhibitors BOEHRINGER INGELHEIM INT (DE) 2008-07-02 CN disclosed
WO-2007132010-A1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-22 WO disclosed
US-20070032514-A1 2,4-diamino-pyrimidines as aurora inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-08 US disclosed
US-20070032514-A1 2,4-diamino-pyrimidines as aurora inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-08 US disclosed
US-20070032514-A1 2,4-diamino-pyrimidines as aurora inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-08 US disclosed
WO-2007003596-A1 2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251174-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS AURKA, AURKC, AURKB JAK3 811/4885AURKA 1/4885EGFR 289/4885
US-20070032514-A1 2,4-diamino-pyrimidines as aurora inhibitors AURKA, AURKC, AURKB JAK3 811/4885AURKA 1/4885EGFR 289/4885
US-20130281429-A1 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS AURKA, AURKC, AURKB JAK3 811/4885AURKA 1/4885EGFR 289/4885
US-20090163467-A1 New compounds CCNA1, MKI67, CCNT1 JAK3 3295/4885AURKA 2076/4885EGFR 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.